From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO – HEAD & NECK
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in head & neck
Dr Marika Rasschaert, a medical oncologist at the University Hospital Antwerp, Belgium, provided a comprehensive overview of critical studies presented at ASCO 2024 in the oral abstract session on Head
Dr Willem Lybaert, medical oncologist at VITAZ Sint-Niklaas and University Hospital Antwerp, presents highlights from the rapid oral abstract session on head & neck cancer. The phase 1 TARGET-HPV trial
Dr Marika Rasschaert, a medical oncologist at the University Hospital Antwerp, Belgium, provided a comprehensive overview of critical studies presented at ASCO 2024 in the Central Nervous System Tumours session.
In-depth stories about head & neck
Head & neck poster selection
The STELLAR 305 clinical trial is a phase 2/3 randomised study comparing pembrolizumab with placebo versus pembrolizumab with zanzalintinib. This study builds on phase 2 trial results using cabozantinib, a
The PEMDA Head and Neck trial investigates the efficacy of a STAT3 inhibitor. Previous studies have shown that STAT3 inhibition, when combined with PD-L1 inhibitors, yields promising results and good